Future Industry Leaders Networking Drinks

Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.

Dr Oliver Hardick is the founder of Puridify, a venture backed bioprocessing technologies company that was recently acquired by GE Healthcare to continue the commercialisation.
Oliver completed his Engineering doctorate at UCL in the department of Biochemical Engineering headed up by Prof Nigel Titchener-Hooker where the initial purification technology, FibroSelect, was developed under the supervision of Prof Dan Bracewell, and Oliver continues to represent UCL as an honorary lecturer. His expertise lie in the field of novel purification approaches in bioprocessing and is experienced at delivering successful large multidisciplinary R&D projects.

Puridify is developing and commercialising novel bioprocessing platform technologies allowing the cost effective manufacture of a wide range of existing and new biomolecule products.
Since incorporation in 2013 Puridify has raised $12 million from both private and public sources and currently has ~20 people working to develop and commercialise the FibroSelect platform technology.

Charlotte is the co-founder and CEO of Theolytics, a pre-clinical biotech company harnessing viruses to combat disease. She is also the Project Lead for Yarvie, a platform supporting life science entrepreneurs to commercialise their technologies.

Prior to joining Theolytics, Charlotte co-founded and led a strategic consulting firm, working with clients to translate novel life science technologies to the point of commercial viability. Previously, she was a curator of the World Economic Forum Global Shapers network; Managing Director of HealthTech Women London; and HelloTomorrow’s London Chair for Healthcare and Medical Technologies.

Charlotte graduated as a University of Cambridge Bioscience Enterprise M.Phil Scholar and was a shortlisted finalist for Cambridge Entrepreneur of the Year. She was the youngest listed 2016 nominee for MT’s 35 under 35 Award.

Dr Toby Basey-Fisher is the CEO and founder of Entia. Toby is also an honorary lecturer at Imperial College London and sits on the Executive Board of the British In-Vitro Diagnostics Association.

Entia is driven by an aspiration to make lives better. Through simple-to-use blood tests and digital monitoring services, the company is able to empower people with new insights to personalise care. The company launched its first product in 2018 across 14 countries and is currently preparing for the launch of two further services.